Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 29;15(5):1047–1055. doi: 10.1016/j.stemcr.2020.10.003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Gli2 Promotes Oligodendrocyte Differentiation from vNSCs

(A) Immunofluorescence for fate-mapped Gli1^NULL vNSCs (green) co-expressing PDGFRα (OPC) or CC1 (OL) (magenta). n = 5 mice/genotype, GFP + cell (arrows) and marker + GFP co-expressing cells (arrowheads).

(B) Quantification of the proportion of GFP + fate-mapped Gli1^HET (white) and Gli1^NULL (green) vNSCs that co-express markers of OPC (PDGFRα) and OL (CC1) in (B).

(C) Immunofluorescence for OPCs (NG2, green) and RFP + Gli1 fate-mapped vNSCs (red) following overexpression (Gli2-OE) or inhibition (GANT58 treatment) of Gli2 in vitro. n = 3 replicates.

(D) Quantification of Gli2 overexpression or inhibition in (C).

(E) Immunofluorescence for MBP + mature OLs (green) and RFP + fate-mapped Gli1 vNSCs (red) following overexpression (Gli2-OE) or inhibition (GANT58 treatment) of Gli2 in vitro. n = 3 replicates.

(F) Quantification of Gli2 overexpression (Gli2-OE) or inhibition (GANT58 treatment) in (E).

One-way ANOVA with Tukey's post-hoc t tests within Gli1 genotypes; all data presented as mean ± SEM. Scale bars, 50 μm. CC, corpus callosum; OPC, oligodendrocyte progenitor cells; OL, oligodendrocyte; CUP, cuprizone diet; Gli2-OE, Gli2-overexpression.